Join
Live feed
·
INSIDERFilingvia Quantisnow
Galectin Therapeutics Inc. logo

Director Freeman Kevin D bought $14,495 worth of shares (5,000 units at $2.90), increasing direct ownership by 11% to 49,769 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
GALT· Galectin Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GALT (Galectin Therapeutics Inc.) and more on Quantisnow.